PROJECT MANAGEMENT GLOBAL
The Place for People in Projects

US Health Systems join forces to launch Truveta Genome Project

January 14, 2025

In a groundbreaking collaboration, leading US health systems have announced the Truveta Genome Project, an ambitious initiative to create the world's largest and most diverse database of genetic information. This project has the potential to revolutionize our understanding of human health and disease.

The Truveta Genome Project will sequence the exomes – the protein-coding regions of genes – of tens of millions of consented and de-identified volunteers. This scale surpasses previous endeavors by more than ten times, ensuring comprehensive representation across ancestries, ethnicities, genders, and other social determinants of health. This diversity is crucial for unlocking a deeper understanding of how genetics influence health outcomes across different populations.

The project is a collaborative effort between Truveta, a data-driven healthcare company, and leading health systems including Advocate Health, CommonSpirit Health, Henry Ford Health, Northwell Health, Providence, and Trinity Health. The Regeneron Genetics Center® (RGC) will sequence the exomes of the first ten million volunteers, while Microsoft Azure will serve as the exclusive cloud provider for the project.

Patient privacy is paramount. Healthcare sites across the US will obtain patient consent to utilize leftover biospecimens from routine lab tests linked to their de-identified medical records for anonymized genetic research. Biospecimens will be sent to RGC for sequencing, ensuring patient anonymity throughout the process.

Unlocking the Power of AI for Medical Breakthroughs

The anonymized sequencing data will be integrated with Truveta Data, a massive dataset of de-identified electronic health records from over 120 million patients. This rich data pool, combined with the power of artificial intelligence (AI), will empower researchers to:

- **Accelerate drug discovery:** By identifying genetic variations associated with specific diseases, researchers can develop more targeted therapies.
- **Optimize clinical trials:** By pinpointing patient populations most likely to respond to specific treatments, clinical trials can be conducted more efficiently.
- **Transform preventative care:** A deeper understanding of genetic predispositions can pave the way for earlier disease detection and prevention strategies.
- **Personalize medicine:** By tailoring treatments to an individual's unique genetic makeup, healthcare can become more precise and effective.

"The Truveta Genome Project has the potential to transform healthcare from treating disease to preventing disease," said Michael Dowling, Northwell Health CEO. This sentiment is echoed by leaders across the participating health systems, who all share a vision of leveraging genomics to revolutionize healthcare delivery.

To make this ambitious project a reality, 17 health systems, Illumina, and Regeneron have invested a combined $320 million in Truveta. This investment underscores the immense potential of the Truveta Genome Project to unlock new medical breakthroughs and improve health outcomes for all.

Interested individuals can visit Truveta.com for more information on how to participate in this groundbreaking initiative. By contributing their anonymized genetic data, they can play a vital role in advancing the future of medicine.

The Truveta Genome Project marks a significant step forward in personalized medicine. With its unprecedented scale, diversity, and commitment to privacy, this project has the potential to transform healthcare delivery and improve the lives of millions.